Literature DB >> 30019650

Significance of miR-15a-5p and CNKSR3 as Novel Prognostic Biomarkers in Non-Small Cell Lung Cancer.

Sercan Ergun1,2, Serkan Güney1, Ebru Temiz3, Nina Petrovic4,5, Sezgin Gunes2,6.   

Abstract

BACKGROUND: In recent years, targeted cancer treatment methods at various molecular levels have been developed for Non-Small Cell Lung Cancer (NSCLC), one of two major subtypes of lung cancer. miRNAbased clinical trials are currently the preferred targeted therapeutic strategy. Also, ceRNAs (competing endogenous RNA) would be the newest and the most effective approach to uncover novel interactions between mRNAs and miRNAs in NSCLC carcinogenesis. There are many factors influencing the efficiency of a miRNA to suppress or silence translation of the target mRNA. The most effective event is the presence of other RNAs showing ceRNA activity. These RNAs contain binding sites for specific miRNAs and enable miRNAs to bind these pseudo targets, instead of the original binding sites on the target mRNA. Therefore, the mRNA of the target gene is less affected by this miRNA, while the amount of miRNA remains the same in the media.
METHOD: For this project, we determined that five clinically important different oncogenes (PDL1, FGFR1, DDX3X, SLC1A5, FXR1 ) are involved in the pathogenesis of NSCLC. For this purpose, we transfected model NSCLC cell line, A549, with miRNAs (miR-150-5p, miR-15a-5p, miR-503-5p) targeting these oncogenes to investigate whether these oncogenes will be suppressed at the mRNA level and also how the suppression efficiency of these miRNA on the oncogenes will be affected by possible ceRNA (CNKSR3, POU2F1, HIPK2) activities.
RESULTS: miR-15a-5p was determined to have the most suppressive effect on the five genes and three potential ceRNAs (p<0.05). Furthermore, CNKSR3 was the ceRNA most affected by all three miRNAs (p<0.05).
CONCLUSION: CNKSR3 was affected more than the oncogenes known to act on NSCLC and this might make it a stronger and novel marker for use in possible treatment regimens designed using miR-15a-5p silencing effect on oncogenes in NSCLC pathogenesis. According to the literature, this is the first study associating NSCLC with miR-15a-5p and CNKSR3. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CNKSR3; NSCLC; ceRNA; miR-15a-5p; miRNA; prognostic biomarkers.

Mesh:

Substances:

Year:  2018        PMID: 30019650     DOI: 10.2174/1871520618666180718100656

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  7 in total

1.  MicroRNA-150-5p and SRC kinase signaling inhibitor 1 involvement in the pathological development of gastric cancer.

Authors:  Xiyun Quan; Dongliang Chen; Ming Li; Xun Chen; Meiyuan Huang
Journal:  Exp Ther Med       Date:  2019-07-30       Impact factor: 2.447

2.  Circular RNA circ-LDLRAD3 serves as an oncogene to promote non-small cell lung cancer progression by upregulating SLC1A5 through sponging miR-137.

Authors:  Min Xue; Weijun Hong; Jun Jiang; Fang Zhao; Xiwen Gao
Journal:  RNA Biol       Date:  2020-07-13       Impact factor: 4.652

3.  MicroRNA‑15a‑5p‑targeting oncogene YAP1 inhibits cell viability and induces cell apoptosis in cervical cancer cells.

Authors:  Xu Chen; Ruiqin Cao; Haifang Liu; Tuanying Zhang; Xinrong Yuan; Shuxiang Xu
Journal:  Int J Mol Med       Date:  2020-08-12       Impact factor: 4.101

4.  LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis.

Authors:  Kai Guo; Di Qi; Bo Huang
Journal:  Cancer Cell Int       Date:  2021-02-01       Impact factor: 5.722

Review 5.  Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.

Authors:  Ilaria Guerriero; Gianni Monaco; Vincenzo Coppola; Arturo Orlacchio
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-22

6.  MEG3 LncRNA from Exosomes Released from Cancer-Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis.

Authors:  Yulu Sun; Guijun Hao; Mengqi Zhuang; Huijuan Lv; Chunhong Liu; Keli Su
Journal:  Yonsei Med J       Date:  2022-03       Impact factor: 2.759

Review 7.  MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Zuha Imtiyaz; Muneeb U Rehman; Rana M Alsaffar; Naveed Nazir Shah; Sultan Alshehri; Mohammed M Ghoneim; Syed Sarim Imam
Journal:  Diagnostics (Basel)       Date:  2022-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.